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The term acute myocardial infarction (MI) should be used when there is evidence of myocardial necrosis in a clinical setting consistent with acute myocardial ischaemia. Under these conditions, any one of the following criteria meets the diagnosis for MI:
Detection of a rise and/or fall of cardiac biomarker values (preferably cardiac troponin [cTn] ) with at least one value above the 99th percentile upper reference limit and with at least one of the following:
• Symptoms of ischaemia.
• New or presumed new significant ST-segment-T wave changes or new left bundle branch block.
• Development of pathological Q waves in the ECG.
• Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.
• Identification of an intracoronary thrombus by angiography or autopsy.
In this context, troponin measurement is only part of the definition of myocardial infarction, and it is implicit in the definition that troponin measurement should be in the context of suspected MI. Similarly, in the most recent guidelines for management of acute coronary syndrome, the pathway is quite clear with history, then electrocardiogram and then troponin measurement. 4 Clinical teaching is that history and examination should preceded test ordering. Laboratory testing is used to refine the diagnostic hypothesis. The interpretation of laboratory results is critically dependant on the clinical context of those results. The impact of prior probability of disease on test performance was eloquently expounded by the Reverend Thomas Bayes in 1763 5 and remains as true now as it was then. Maintaining the proud tradition of Scottish scholarship, the recent paper by Shah et al., recently published in the British Medical Journal, makes interesting reading. 6 They prospectively examined three independent consecutive patient populations presenting to emergency departments. High sensitivity cardiac troponin I (hs cTnI) concentrations (Abbott diagnostics, 10% CV 4.7 ng/L, 99th percentile 34 ng/L in men and 16 ng/L in women) were measured in 8500 patients. There were three populations, unselected patients attending the emergency department (ED) in the UK (n ¼ 1054) and two selected populations (troponin testing was requested by the attending clinician) in the UK (n ¼ 5815) and the US (n ¼ 1631). The final diagnosis of type 1 or type 2 myocardial infarction or myocardial injury was independently adjudicated.
There was elevation of hs cTnI in 13.7% (144/1054) in the unselected population attending the ED in the UK. Divided by final diagnosis, 17 (1.6%) patients were classified as type 1 myocardial infarction, 13 (1.2%) as type 2 myocardial infarction, and 114 (10.8%) as myocardial injury, respectively. This gave a prevalence of 1.6% (17/1054) for type 1 myocardial infarction and a positive predictive value of 11.8% (95% confidence interval 7.0% to 18.2%).
In the selected UK population, hs cTnI was elevated in 24.1% (1403/5815) of all patients. Type 1 myocardial infarction was adjudicated in 68 (4.2%) patients, with 102 (6.3%) and 245 (15.0%) patients classified as having type 2 myocardial infarction and myocardial injury, respectively. In the selected population in the US, hs cTnI was elevated in 25.4% (415/1631), with type 1 myocardial infarction adjudicated in 68 (4.2%) patients and 102 (6.3%) classified as having type 2 myocardial infarction and 245 (15.0%), patients with myocardial injury. In selected patients, in whom troponin testing was guided by the attending clinician, the prevalence and positive predictive value were 14.5% (843/ 5815) and 59.7% (57.0% to 62.2%) in the UK and 4.2% (68/1631) and 16.4% (13.0% to 20.3%) in the US. Across both selected patient populations, the positive predictive value was highest in patients with chest pain, with ischaemia on the electrocardiogram, and with a history of ischaemic heart disease. They observe that widespread troponin testing occurs and is of significantly reduced diagnostic efficiency without prior patient selection. The Reverend Bayes would be proud of them.
Is this likely to be widespread? Sadly, yes. An audit of activity at St George's showed that in January, we performed 10,021 troponin tests (high sensitive cardiac troponin T). Of these, 65% were single tests and only 21.4% serial. Although there are clear clinical definitions, endorsed internationally, 1 and guidelines endorsed by professional societies, 4 it is apparent that troponin testing seems to work on the basis of a diagnostic algorithm 'pain between knees and nose measure troponin and refer' or possibly 'patient looks a bit peaky, measure troponin and refer'.
How did we arrive at this point? There may be a number of factors. Certainly the use of nurse based triage and pre-ordering of test panels prior to medical assessment may be a contributory, perhaps driven by the 4 h target. Laboratories may also be victims of their own success. We now provide a range of diagnostic testing 24 h a day with good turnaround times. When you provide an excellent service, it will be used. It may represent an over reliance of a new generation of physicians on laboratory testing and imaging. Certainly diagnostic modalities have tremendously improved especially the diagnostic accuracy of cross sectional imaging. Perhaps we have oversold troponin. Originally marketed as a test specific for myocardial infarction, progressive improvement in assay sensitivity has shown that troponin elevation outside ACS is widespread, as Shah et al. document. Indeed, they show that type 2 MI and myocardial injury (secondary myocardial injury) is the predominant type. This does not detract from the ability of troponin to demonstrate clinically significant myocardial injury. It is important to remember that the presence of myocardial injury, regardless of cause, has prognostic significance. Their study highlights the need to distinguish acute myocardial injury from chronic myocardial injury and recognize acute myocardial infarction as a subtype of acute myocardial injury. 7 Most importantly, it highlights the need for appropriate patient selection before testing.
As the world moves to implementation of high sensitivity troponin testing, it is apparent that clinician education in appropriate patient testing and sensible result interpretation is required. There appears to be a general lack of consensus on how high sensitivity troponin should be implemented and used. 8 The need for laboratory/clinician interaction is paramount 9 although this is apparently exception rather than the rule. 10 We clearly need to work harder. Go forth and educate!
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